Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug

 

• Regeneron Pharmaceuticals Inc's 
  REGN+18.9%+ Free Alerts
   two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary endpoints in diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). 
• The PHOTON trial in DME and the PULSAR trial in wAMD achieved non-inferiority in vision gains compared to the currently-approved 2 mg Eylea 8-week dosing regimen. 
• 91% and 89% of DME patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without the need for regimen modification) through week 48, respectively.
• 79% and 77% of wAMD patients were rapidly initiated and maintained on 12- and 16-week dosing intervals.
• The safety of aflibercept 8 mg was similar to Eylea and consistent with the well-established safety profile of Eylea from previous clinical trials.
• Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG 
  BAYRY
  . In the U.S., Regeneron maintains exclusive rights to Eylea and aflibercept 8 mg. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of Eylea.

https://www.benzinga.com/general/biotech/22/09/28794390/new-data-favors-higher-dose-of-regenerons-flagship-eye-disease-drug